CNP three-lens brief
Evidence-based stock research on CNP. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Negative free cash flow last quarterly (-$4.95B).
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Negative free cash flow last quarterly (-$4.95B).
- Debt-to-equity of 216% — balance-sheet-heavy.
- Earnings scheduled 2026-07-23.
CNP closed at $43.58 (+0.60%) as of 2026-07-10. Market cap: $28.51B. P/E (trailing) 26.7. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.. Concerns: negative free cash flow last quarterly (-$4.95B).; debt-to-equity of 216% — balance-sheet-heavy.. Last quarter: Revenue $2.98B, net income $316.00M, free cash flow -$4.95B. Watching for: 2026-07-23 earnings release (12 days out).
Why three lenses on CNP, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CNPacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CNP" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CNP brief"></iframe>